sellWeak cluster of 2
N Anthony Coles sold $104k of CERE
director at Cerevel Therapeutics Holdings, Inc.. 2,506 shares at an average of $41.54, traded Feb 7, 2024, filed Feb 8, 2024.
Warning score
23Value
$104k
2,506 shares
Holdings after
15,638
-14% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +10Trade size$104k at market
- +5Share of holdings soldSold 14% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-012953, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2024 | MOption exercise Common Stock | +15,440 | - | - | 18,144 | Feb 8, 2024 |
| Feb 7, 2024 | SOpen-market sale Common Stock | -2,506 | $41.54 | $104k | 15,638 | Feb 8, 2024 |
| Feb 6, 2024 | MOption exercise Restricted Stock Unitsderivative | -15,440 | $0.00 | $0 | 46,322 | Feb 8, 2024 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% | |
| 51Moderate | Cerevel Therapeutics Holdings, Inc. | Susan ALTSCHULLER Chief Financial Officer | $572k 13,808 shares | -45% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.